Abstract:Uncontrollable cell proliferation and irreversible neurological damage make glioma one of the most deadly diseases in clinic. Besides the multiple biological barriers, glioma stem cells (GSCs) that are responsible for the maintenance and recurrence of tumor tissues also hinder the therapeutic efficacy of chemotherapy. Therefore, all-stage precisional glioma targeted therapy regimens that could efficiently deliver drugs to glioma cells and GSCs after overcoming multiple barriers have received increasing scrutiny. Methods: A polymeric micelle-based drug delivery system was developed by modifying a "Y-shaped" well-designed ligand of both GRP78 protein and quorum sensing receptor to achieve all-stage precisional glioma targeting, then we evaluated the targeting ability and barrier penetration ability both in vitro and in vivo. In order to achieve all-stage precisional therapy, we need kill both GSCs and glioma related cells. Parthenolide (PTL) has been investigated for its selective toxicity to glioma stem cells while Paclitaxel (PTX) and Temozolomide (TMZ) are widely used in experimental and clinical therapy of glioma respectively. So the in vivo anti-glioma effect of combination therapy was evaluated by Kaplan-Meier survival analysis and immunohistochemical (IHC) examination of tumor tissues. Results: The "Y-shaped" well-designed peptide, termed (D)WVAP, exhibited excellent glioma (and GSCs) homing and barrier penetration ability. When modified on micelle surface, (D)WVAP peptide significantly enhanced accumulation of micelles in brain and glioma. In addition, (D)WVAP micelles showed no immunogenicity and cytotoxicity, which could guarantee their safety when used in vivo. Treatment of glioma-bearing mice with PTL loaded (D)WVAP modified PEG-PLA micelles plus PTX loaded (D)WVAP modified PEG-PLA micelles or PTL loaded (D)WVAP modified PEG-PLA micelles plus TMZ showed improved anti-tumor efficacy in comparison to PTL and PTX loaded unmodified micelles or PTL loaded unmodified micelles plus TMZ. Conclusion: Combination of all-stage targeting strategy and concomitant use of chemotherapeutics and stem cell inhibitors could achieve precise targeted therapy for glioma

Glioma Targeting Peptide in Combination with the P53 C Terminus Inhibits Glioma Cell Proliferation in Vitro

Inhibition of Cell Proliferation, Migration and Invasion by A Glioma-Targeted Fusion Protein Combining the P53 C Terminus and Mdm2-Binding Domain

Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Inhibition of Glioma Cell Growth and Apoptosis Induction Through Targeting Wnt10B Expression by Pyrazolo[4,3-c]pyridine-4-one.

Targeted Gene Delivery to Glioblastoma Using a C-end Rule RGERPPR Peptide-Functionalised Polyethylenimine Complex

All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide

Effect of p53 targeting small molecule RITA combined with temozolomide on the growth of glioma cells in vitro

Glioma-Targeted Drug Delivery Enabled by A Multifunctional Peptide

Repression of PCGF1 Decreases the Proliferation of Glioblastoma Cells in Association with Inactivation of C-Myc Signaling Pathway

Chlorotoxin fusion protein regulates miR-374a and TNFAIP8 expression and inhibits glioma cell proliferation and promotes apoptosis

Glioma and Microenvironment Dual Targeted Nanocarrier for Improved Antiglioblastoma Efficacy

Targeted Delivery Of A Novel Palmitylated D-Peptide For Antiglioblastoma Molecular Therapy

Retro-inverso CendR peptide-mediated polyethyleneimine for intracranial glioblastoma-targeting gene therapy.

A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation

RGD Peptide Conjugation Results in Enhanced Antitumor Activity of PD0325901 Against Glioblastoma by Both Tumor-Targeting Delivery and Combination Therapy.

Inhibition of EGR1 Inhibits Glioma Proliferation by Targeting CCND1 Promoter

Crgdyk-Modified Procaine Liposome Inhibits the Proliferation and Motility of Glioma Cells Via the ERK/p38MAPK Pathway

Effects of Caspase-3 and of Glypicante1 altered expressions on proliferation of glioma cells and its mechanism

Nanoparticles Functionalized with Pep-1 As Potential Glioma Targeting Delivery System Via Interleukin 13 Receptor Α2-Mediated Endocytosis.

Enhanced Glioma-Targeting and Stability of LGICP Peptide Coupled with Stabilized Peptide DA7R